Cipher Pharmaceuticals Inc.
TSX:CPH.TODrug Manufacturers - Specialty & Generic
+$0.15 today
- Market cap
- $331.67M
- Beta
- 0.48
- P/E (TTM)
- 9.3
- EPS (TTM)
- $1.22
Volume 0.04M
Average 0.03M
CPH.TO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Cipher Pharmaceuticals Inc.TSX: CPH.TO
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $2.85M fell 41.0% year over year, behind the -6.3% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 28.2% from the prior quarter. Over 3 fiscal years it compounded at +54.7% a year.
Context
- Selling, general & admin amounted to 31.8% of revenue in FY2025, down 4.9 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $13.9M (-14.7%) for the fiscal year ending Dec 2026, a slowdown from the +33.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $2.85M-28.2% QoQ
- Last fiscal yearDec 2025
- $16.3M+33.2% YoY
- LTMMar 2026
- $14.61M-6.3% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 16.3M USD
- Year-over-year change
- +33.2%
- 4-year CAGR
- +33.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.3M | +33.2% |
| FY2024 | 2024-12-31 | 12.24M | +125.6% |
| FY2023 | 2023-12-31 | 5.43M | +23.3% |
| FY2022 | 2022-12-31 | 4.4M | -13.9% |
| FY2021 | 2021-12-31 | 5.11M | — |
Selling, General & Admin vs competitors
How CPH.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -6.3% is the 6th highest of 8, against a peer median of +1.0%.
- Selling, general & admin amounts to 28.7% of revenue for CPH.TO, versus a peer median of 39.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$164.92M CAD | -0.9% | -1.8% | 51.8% | |
| LTM Mar 2026 | CA$132.41M CAD | +29.4% | +11.8% | 25.9% | |
| LTM Mar 2026 | CA$122.93M CAD | +1.0% | -25.6% | 39.5% | |
| LTM Mar 2026 | CA$92.99M CAD | +36.2% | — | 33.9% | |
| LTM Mar 2026 | $84.46M USD | -22.8% | -10.9% | 32.3% | |
| LTM Mar 2026 | $53.08M USD | +34.4% | +31.8% | 103.7% | |
| LTM Mar 2026 | $14.61M USD | -6.3% | +54.7% | 28.7% | |
| LTM Mar 2026 | CA$7.33M CAD | -43.7% | +10.7% | 265.4% | |
| Peer median (excluding CPH.TO) | — | +1.0% | +4.5% | 39.5% | |
Competitors are the stored peer set for CPH.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 21.94M | 20.68M | 21.16M | 33.36M | 51.33M |
| Cost of Revenue | 3.68M | 3.99M | 4.07M | 9.26M | 17.56M |
| Gross Profit | 18.26M | 16.68M | 17.09M | 24.1M | 33.77M |
| Gross Margin | 83.2% | 80.7% | 80.8% | 72.2% | 65.8% |
| Research & Development | 88K | 98K | 139K | 0 | 21.37K |
| Selling, General & Admin | 5.11M | 4.4M | 5.43M | 12.24M | 16.3M |
| Operating Expenses | 6.45M | 5.63M | 5.56M | 16.26M | 16.97M |
| Depreciation & Amortization | 701K | 989K | 1.23M | 4.02M | 7.23M |
| EBITDA | 13.66M | 12.04M | 11.53M | 11.87M | 24.1M |
| EBITDA Margin | 62.2% | 58.2% | 54.5% | 35.6% | 46.9% |
| Operating Income | 11.82M | 12.04M | 11.53M | 7.85M | 16.8M |
| Operating Margin | 53.9% | 58.2% | 54.5% | 23.5% | 32.7% |
| Interest Income | 12K | 464K | 1.87M | 330K | 0 |
| Interest Expense | 92K | 0 | 0 | 0 | 1.19M |
| Other Income / Expenses | (2M) | (560K) | 1.15M | (4.89M) | 661.38K |
| Income Before Tax | 11.06M | 11.48M | 12.68M | 2.96M | 17.46M |
| Pre-Tax Margin | 50.4% | 55.5% | 59.9% | 8.9% | 34.0% |
| Income Tax Expense | 3.3M | (15.16M) | (7.7M) | (8.59M) | (10.34M) |
| Net Income | 7.76M | 26.64M | 20.38M | 11.55M | 27.81M |
| Net Margin | 35.4% | 128.8% | 96.3% | 34.6% | 54.2% |
| EPS (Basic) | 0.29 | 1.06 | 0.80 | 0.47 | 1.09 |
| EPS (Diluted) | 0.29 | 1.04 | 0.80 | 0.47 | 1.07 |
| Weighted Avg Shares | 26.6M | 25.13M | 25.48M | 24.72M | 25.48M |
| Weighted Avg Shares (Diluted) | 26.83M | 25.59M | 25.42M | 24.57M | 25.99M |
Cipher Pharmaceuticals Inc.
TSX:CPH.TO
Intrinsic Alpha fair value
Locked
Current Price
$13.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.